1012 related articles for article (PubMed ID: 18612161)
21. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
Jacobs JF; Nierkens S; Figdor CG; de Vries IJ; Adema GJ
Lancet Oncol; 2012 Jan; 13(1):e32-42. PubMed ID: 22225723
[TBL] [Abstract][Full Text] [Related]
22. Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma.
Matikas A; Mavroudis D
Future Oncol; 2015; 11(6):997-1009. PubMed ID: 25760979
[TBL] [Abstract][Full Text] [Related]
23. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
24. Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma.
Hsueh EC; Famatiga E; Shu S; Ye X; Morton DL
Ann Surg Oncol; 2004 Oct; 11(10):892-9. PubMed ID: 15383418
[TBL] [Abstract][Full Text] [Related]
25. Treatment of metastatic melanoma: an overview.
Bhatia S; Tykodi SS; Thompson JA
Oncology (Williston Park); 2009 May; 23(6):488-96. PubMed ID: 19544689
[TBL] [Abstract][Full Text] [Related]
26. Update on immunotherapy for melanoma.
Ribas A
J Natl Compr Canc Netw; 2006 Aug; 4(7):687-94. PubMed ID: 16884670
[TBL] [Abstract][Full Text] [Related]
27. [New aspects of immunotherapy of malignant melanoma].
Enk A
Praxis (Bern 1994); 2001 Mar; 90(10):403-6. PubMed ID: 11305186
[TBL] [Abstract][Full Text] [Related]
28. The role of the CTLA4 blockade in the treatment of malignant melanoma.
Cranmer LD; Hersh E
Cancer Invest; 2007 Oct; 25(7):613-31. PubMed ID: 18027152
[TBL] [Abstract][Full Text] [Related]
29. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
Korman A; Yellin M; Keler T
Curr Opin Investig Drugs; 2005 Jun; 6(6):582-91. PubMed ID: 15988909
[TBL] [Abstract][Full Text] [Related]
30. [Antibody therapies for melanoma].
Kiniwa Y; Okuyama R
Nihon Rinsho; 2012 Dec; 70(12):2172-6. PubMed ID: 23259392
[TBL] [Abstract][Full Text] [Related]
31. A role of immunotherapy in metastatic malignant melanoma.
Allen T; Gundrajakuppam L
Cent Nerv Syst Agents Med Chem; 2012 Sep; 12(3):182-8. PubMed ID: 22697295
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy of malignant melanoma.
Oratz R; Bystryn JC
Dermatol Clin; 1991 Oct; 9(4):669-82. PubMed ID: 1718648
[TBL] [Abstract][Full Text] [Related]
33. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
Lotem M; Merims S; Frank S; Ospovat I; Peretz T
Harefuah; 2012 Oct; 151(10):585-8, 604. PubMed ID: 23316667
[TBL] [Abstract][Full Text] [Related]
34. Despite past disappointments, the future of melanoma therapy appears bright.
Tarhini A
Oncology (Williston Park); 2009 May; 23(6):509, 515. PubMed ID: 19544692
[No Abstract] [Full Text] [Related]
35. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
36. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic use of anti-CTLA-4 antibodies.
Blank CU; Enk A
Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
[TBL] [Abstract][Full Text] [Related]
38. Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma.
Marshall JA; Forster TH; Purdie DM; Lanagan CM; O'Connor LE; O'Rourke MG; Johnson MK; See JL; Ellem KA; Martinez NR; López JA; Schmidt CW
Immunol Cell Biol; 2006 Jun; 84(3):295-302. PubMed ID: 16681827
[TBL] [Abstract][Full Text] [Related]
39. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
40. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
Weber J
Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
